Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.

Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol. 2010 Jan; 12(1):14-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.